The World Health Organization (WHO) recommends an initial treatment regimen for tuberculosis in children that is comparable to that for adults, with directly monitored multiple-drug therapy for 6 months. Early initiation of treatment in younger children is essential due to the possibility of rapid dissemination of the disease, severe sequelae, and death. Children and adolescents usually tolerate antituberculosis drugs very well. This article aims to review the main therapeutic regimens, dosages, and adverse effects associated with first-line drugs used in treatment regimens for tuberculosis in children and to provide some practical recommendations for the follow-up of children and adolescents undergoing treatment. The article reviews current guidelines from the WHO and the Brazilian Ministry of Health as well as currently used therapeutic regimens and their main adverse effects. The reviewed literature states that at recommended doses, antituberculosis drugs are well tolerated by the pediatric population, and severe adverse effects are rare and mostly temporary. The frequency of toxic effects may be related to disease severity. Isoniazid is the most extensively studied drug and the most commonly used in children because it is also used in the treatment of latent tuberculosis. Liver toxicity is the primary described adverse effect. In most cases, when treatment is started adequately on time, it proceeds without severe adverse effects that require the therapy to be suspended. A high degree of suspicion is required to establish the diagnosis and consequently the adequate treatment, aiming for a long-term change in the course of the disease in children.
INTRODUCTION
The World Health Organization (WHO) estimates that 950,000 children and adolescents of < 15 years developed tuberculosis (TB) in 2015, accounting for 10% of all cases.
Approximately 210,000 of them died as a result of the disease
.
With regard to the global prevalence of TB in children, it is generally agreed that there are a large number of undiagnosed and consequently untreated children [2] [3] [4] . This is probably because, for many years, TB control programs focused only on adults with bacilliferous pulmonary disease and also because of the difficulties in confirming TB diagnosis in childhood.
TB is a disease with worldwide distribution and caused Children of < 5 years exposed to and infected by M. tuberculosis have a greater risk of progressing to active disease than older children (5-14 years old) 5, 6 . They also have a greater probability of developing severe forms of the disease, such as tuberculous meningitis, and have a higher mortality rate than do older children [6] [7] [8] .
The WHO recommends an initial treatment regimen for tuberculosis in children that is comparable to that for adults, with directly monitored multiple-drug therapy for 6 months 9 . It is essential to start the treatment early in younger children because of the possibility of rapid disease dissemination, severe sequelae, and death 
Treatment regimen for tuberculosis in children
The best treatment regimen for TB should meet the following recommendations: early bactericidal activity, capable of preventing the appearance of drug-resistant bacilli, and sterilizing activity
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. For treating children of <10 years with drug-sensitive pulmonary or extrapulmonary TB (except tuberculous meningoencephalitis), the Brazilian
Ministry of Health recommends a 2-month loading phase with rifampicin, isoniazid, and pyrazinamide, followed by a 4-month maintenance phase with rifampicin and isoniazid. In children of ≥ 10 years, ethambutol is added to the loading phase
. Tables   1 and 2 present the dosage according to age range and weight. When treating tuberculous meningoencephalitis and osteal TB, the WHO advises the maintenance phase to be extended to 10 months; the total length of the treatment will therefore be 12 months (Table 3) . For tuberculous meningitis, corticosteroids should be added to the regimen to improve survival and reduce mortality. Prednisone or prednisolone (1-2 mg/kg/day) is most frequently used; in more severe cases, up to 4 mg/kg/day may be prescribed, with a maximum dose of 60 mg/day for 4 weeks. In very severe cases, intravenous corticosteroids, such as dexamethasone at 0.3-0.4 mg/kg/day may be used for 4-8 weeks. The dose must be gradually reduced in the last 2 weeks until complete suspension. In such cases, early initiation of physical rehabilitation treatment with motor therapy is of paramount importance to reduce morbidity
.
First-line antituberculosis drugs Isoniazid
Isoniazid has great bactericidal power and acts on all sensitive bacillus populations, whether they are intracavitary, in granulomas, or intracellular. It is highly soluble in water In Brazil, isoniazid is available as 100mg tablets or associated with other drugs, as described in Table 4 .
Some facilities use compounded isoniazid preparations for children, but in such cases, special attention must be given to the preparation's expiration date and guarantee of efficacy.
In 2016, water-dispersible tablets for pediatric use were introduced, but they are not yet available in Brazil. This new preparation has several advantages, such as better taste, easier preparation by parents or guardians, and possible combination of formulations with other drugs, as in those used for adults. 
Rifampicin
Rifampicin has great bactericidal power and the greatest sterilizing power of all antituberculosis drugs. It is because of this drug that the duration of TB treatment course is 6 months; in special regimens without rifampicin, due to adverse effects or tolerability problems, the treatment must be extended to 1 year. Rifampicin is highly lipophilic and can enter the central nervous system in the presence of inflammation and consequently disrupt the blood-brain barrier. It is metabolized chiefly in the enterohepatic circulation
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Rifampicin is a potent inducer of several enzymes involved in drug metabolism. It also induces the P-glycoprotein . This makes treatment of co-infected HIV/AIDS patients more difficult.
Currently recommended doses of rifampicin are well tolerated by children, and allergic or hepatotoxic adverse effects are rare. On the other hand, adverse effects are widely reported in adults and more commonly seen when high and intermittent doses are taken. There can be reactions such as fever, skin rashes, flu-like syndrome, eosinophilia, and less frequently hemolytic anemia and acute kidney failure 19 .
In Brazil, rifampicin is available as a solution (20 mg/mL) and in capsules (300 mg). There are also combined preparations, as described in Table 4 .
Pyrazinamide
Pyrazinamide is produced as a crystalline powder with low water solubility, forming suspensions that sediment easily. 20 . Liver enzyme abnormalities were infrequent and temporary, and the drug was well tolerated, even when it was used in chemoprophylaxis regimens 15, 20 .
In Brazil, pyrazinamide is available as a solution (30 mg/mL), in capsules (500 mg), and in combination with other drugs, as described in Table 4 .
Ethambutol
The last drug of those considered to be the first-line treatment for TB, ethambutol is bacteriostatic, and it is used in combined therapeutic regimens. Its concentration in the central nervous system is low 9 . Its use in association with more potent drugs is intended to prevent the emergence of drug-resistant bacilli. In Brazil, it is currently used in basic treatment regimens for children and adolescents of ≥ 10 years, and it is not part of the initial scheme for younger children. This is not because of possible toxic effects, as many believe, but rather because of the low risk for primary resistance in this population and because suitable ethambutol formulations for the pediatric age range are unavailable.
The most severe toxic effect of ethambutol is retrobulbar neuritis, which is reversible when detected early.
This effect is related to dosage and treatment duration In Brazil, ethambutol is available only in coated tablets at a dose of 400 mg and also in combination with other drugs, as described in Table 4 . The management of drug-resistant TB in pediatrics is similar to that in adults, prioritizing shorter regimens. However, the use of second-line antituberculosis drugs in children is complicated by the absence of pediatric formulations of most drugs, which may lead to under or overdosage 1, 10 . In some cases, personalized treatment regimens have been necessary for pediatric patients, and the results have been satisfactory, as described in a retrospective study of 149 children of < 15 years with documented or suspected drug-resistant TB in South Africa. Treatment regimens included four active drugs and one injectable agent for 66% of the patients, and they were administered for an average of 13 months; either confirmed or likely cure was obtained in 92% of the patients
Treatment for drug-resistant tuberculosis in children

.
MDR-TB treatment duration is longer and requires the use of second-line drugs, with more adverse effects. However, there is little information in the literature about the safety and tolerability of these drugs in children 27 . Generally, MDR-TB treatment in pediatric patients has an 80% success rate compared with approximately 60% in adults 11, 26, 28 . Children and adolescents under special regimens for drug-resistant TB must be frequently re-evaluated for adherence, therapeutic response, and potential adverse effects.
What is necessary during treatment besides drugs?
The WHO recommends that children and adolescents and it is difficult to determine which drug is responsible for the adverse effect when both therapies are combined
.
The WHO strategy for the elimination of TB targets a substantial reduction in the incidence of the disease and its mortality rates and provides opportunities to conduct pediatric TB treatment on a large scale
Because TB is predominantly paucibacillary and presents nonspecific clinical forms in children, it becomes a challenge for health professionals. Therefore, a high degree of suspicion is needed to diagnose the disease and consequently treat it adequately, aiming for a long-term change of the disease course in pediatric patients. In the vast majority of cases, when treatment is adequately instituted, it proceeds without important adverse effects that would require it to be suspended.
During treatment, attention must be given to the prescription of adequate doses for the child's weight, adherence to treatment, presence of adverse effects, possibility of drug interactions, and clinical course of the patient, with the goal of obtaining a better therapeutic response.
